In this study we have investigated the anticancer activity of piperlongumine, a well-known ROS-inducing anticancer agent (Kung et al., 2021; Pan et al., 2022) and show for the first time that this compound is an NR4A1 ligand acting as an inverse agonist in colon cancer cells. The gene discussed is NR4A1; the disease is colonic neoplasm.